Shield Therapeutics is a specialty pharmaceutical company focused on the development and commercialisation of late‑stage, hospital‑focused pharmaceuticals which address areas of unmet medical need.
Find out moreOur lead product, Ferric Maltol, is a novel oral ferric iron therapy approved by the FDA and will be marketed in the US as Accrufer® and is also approved by the EMA and Swiss Medic and marketed in the European Union as Feraccru® by our commercial partner, Norgine BV.
Find out moreTim Watts our CFO recently presented at the London South East/Hardman & Co 'Life Sciences Investor Briefing' - watc… https://t.co/fQXVyOcgda
RT @WalbrookPR: ***LISTEN*** Carl Sterritt, CEO of @ShieldTx (AIM: #STX), on BBC World Business Report - 'Why investors returns are dictati…
RT @LondonSouthEast: Our sincere thanks to Life Sciences companies @DestinyPharma @ShieldTx and @OpenOrphan for speaking at our joint @Ha…
